Product Description:
Amoxicillin 600 mg in 5 ml, Potassium Clavulanate 42.9 mg in 5 ml:
Amoxicillin 600 mg in 5 ml and Potassium Clavulanate 42.9 mg powder for oral suspension does not contain the same amount of clavulanic acid (as the potassium salt) as any of the other Augmentin suspensions.
Amoxicillin 600 mg in 5 ml and Potassium Clavulanate powder for oral suspension contains 42.9 mg of clavulanic acid per 5 ml.
Therefore, Megamox 200 mg / 28.5 mg / 5 ml and 400 mg / 57 mg / 5 ml suspensions should not be substituted with Amoxicillin 600 mg in 5 ml and Potassium Clavulanate powder for oral suspension as they are not interchangeable.
Directions for Use:
Pediatric patients aged 3 months and older:
Based on the amoxicillin component (600 mg / 5 ml), the recommended dose of Amoxicillin 600 mg in 5 ml and Potassium Clavulanate powder for oral suspension is 90 mg/kg/day divided every 12 hours.
Instructions for Mixing Oral Suspension:
Prepare the suspension at the time of dispensing as follows:
Tap the bottle until the powder flows freely.
Add approximately 2/3 of the total amount of water for reconstitution and shake vigorously to suspend the powder.
Add the remaining water and shake vigorously again.
Amoxicillin 600 mg in 5 ml, Potassium Clavulanate 42.9 mg powder for oral suspension.
Amount of water required for reconstitution:
75 ml: 70 ml
125 ml: 110 ml
200 ml: 180 ml
Each teaspoon (5 ml) will contain 600 mg of Amoxicillin as trihydrate and 42.9 mg of Clavulanic acid as the potassium salt.
Note:
Shake the oral suspension well before use.
Warnings and Precautions:
These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens.
There have been reports of individuals with a history of penicillin hypersensitivity who experienced severe reactions when treated with cephalosporins.
Before starting treatment with Megamox ES 600 mg, a careful inquiry should be made regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens.
If an allergic reaction occurs, Megamox ES 600 mg should be discontinued and appropriate therapy initiated.
Serious anaphylactic reactions require emergency treatment with adrenaline.
Oxygen, intravenous steroids, and airway management, including intubation, may also be required.
Since Megamox ES 600 mg contains amoxicillin, an aminopenicillin, it is not the treatment of choice for patients with sore throat or pharyngitis due to the possibility that the underlying cause is infectious mononucleosis, in the presence of which there is a high incidence of skin rash if amoxicillin is used.
Megamox ES 600 mg should be avoided if infectious mononucleosis is suspected.
Changes in liver function tests have been observed in some patients receiving the medication.
Hepatic function should be monitored at regular intervals.
Transient hepatitis and cholestatic jaundice have been reported.
Megamox ES 600 mg should be used with caution in patients with evidence of hepatic impairment.
In patients with moderate or severe renal impairment, the dose should be adjusted according to the degree of impairment.
Ingredients:
Amoxicillin 600 mg in 5 ml, Potassium Clavulanate 42.9 mg in 5 ml.
Product Details:
Product Form: Suspension
Product Type: Suspension
Brand: Megamox
Concentration: 600 mg
Quantity: 1 Piece
